

Resource Summary Report

Generated by NIF on Jul 29, 2026

PerCP anti-human CD45

RRID:AB_893337

Type: Antibody

Proper Citation

BioLegend Cat# 304026, RRID:AB_893337

Antibody Information

URL: http://antibodyregistry.org/AB_893337

Proper Citation: BioLegend Cat# 304026, RRID:AB_893337

Target Antigen: CD45

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP anti-human CD45

Description: This monoclonal targets CD45

Target Organism: human

Clone ID: Clone HI30

Antibody ID: AB_893337

Vendor: BioLegend

Catalog Number: 304026

Alternative Catalog Numbers: 304025

Record Creation Time: 20250820T033550+0000

Record Last Update: 20250820T164031+0000

Ratings and Alerts

No rating or validation information has been found for PerCP anti-human CD45.

No alerts have been found for PerCP anti-human CD45.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Chen YL, et al. (2026) Endometrial stromal cell-derived TMAO sustains decidualization to prevent recurrent spontaneous abortion. Cell metabolism.

Fang Y, et al. (2025) Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. STAR protocols, 6(2), 103810.

Li YR, et al. (2025) Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture. Nature protocols, 20(5), 1352.

Li B, et al. (2025) Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis. Cell, 188(14), 3823.

Lam N, et al. (2025) Asynchronous aging and turnover of human circulating and tissue-resident memory T cells across sites. Immunity, 58(9), 2271.

Li YR, et al. (2025) Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med (New York, N.Y.), 100804.

Li YR, et al. (2025) Protocol to profile tumor and microenvironment from ovarian cancer patient samples and evaluate cell-based therapy using in vitro killing assays. STAR protocols, 6(2), 103742.

Vu LT, et al. (2024) Single-cell transcriptomics of the immune system in ME/CFS at baseline and following symptom provocation. Cell reports. Medicine, 5(1), 101373.

Li YR, et al. (2023) Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. iScience, 26(10), 107952.

Middelburg J, et al. (2023) The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent. Cell reports, 42(12), 113516.

Ma X, et al. (2023) Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN- γ axis. Cell reports, 42(8),

112944.

Nuñez NG, et al. (2023) Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. *Med (New York, N.Y.)*, 4(2), 113.

Laforêts F, et al. (2023) Semi-supervised analysis of myeloid and T cell behavior in ex vivo ovarian tumor slices reveals changes in cell motility after treatments. *iScience*, 26(4), 106514.

Vlassis A, et al. (2023) CRISPR-Cas12a-integrated transgenes in genomic safe harbors retain high expression in human hematopoietic iPSC-derived lineages and primary cells. *iScience*, 26(12), 108287.

Li YR, et al. (2022) Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers. *iScience*, 25(9), 104859.

Hu Y, et al. (2022) Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. *Cell research*, 32(11), 995.

Parent AV, et al. (2021) Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection. *Cell reports*, 36(7), 109538.

Li YR, et al. (2021) Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. *Cell reports. Medicine*, 2(11), 100449.

Abdul-Jawad S, et al. (2021) Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. *Cancer cell*, 39(2), 257.

Szabo PA, et al. (2021) Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. *Immunity*, 54(4), 797.